Outcome of patient undergoing redo mitral valve surgery with incidence rate of mitral valve infective endocarditis.
Humans
Male
Female
Middle Aged
Reoperation
/ statistics & numerical data
Mitral Valve
/ surgery
Incidence
Retrospective Studies
Saudi Arabia
/ epidemiology
Endocarditis
/ surgery
Adult
Aged
Hospital Mortality
Heart Valve Prosthesis Implantation
/ adverse effects
Postoperative Complications
/ epidemiology
High risk redo mitral valve
Redo mitral valve concomitant procedures
Redo mitral valve infective endocarditis
Reoperative mitral valve surgery
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
received:
05
06
2024
accepted:
15
09
2024
medline:
2
10
2024
pubmed:
2
10
2024
entrez:
1
10
2024
Statut:
epublish
Résumé
The incidence of infective endocarditis (IE) in patients undergoing redo mitral valve (MV) surgery was evaluated. The outcomes of all the patients and the patients' specific characteristics were recorded. The patients were analyzed to further the research of IE in this population. This was a retrospective review of patients admitted for redo MV surgery with a prospective follow-up of electronic medical records at King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, from 2009 to 2019. Pre/intra/post-operative factors contributing to mortality, morbidity, and freedom of adverse events were analyzed. A total of 211 patients underwent redo MV surgery, and 41 patients (19.4%) had IE; and 51% of this subset of patients, 21 individuals, developed IE after the initial MV surgery. MV stenosis was moderate/severe in 50 patients. Furthermore, MV regurgitation was present in 89 patients. Multivariate analysis of the data revealed multiple factors influencing mortality: age, peripheral vascular disease, concomitant procedures, peripheral vascular disease, red blood cell transfusions, preoperative mechanical valves, and active IE. In-hospital Mortality was 10.9%. The one-, five-, and ten-year survival was 88%, 79%, and 69% across all patients. Although redo MV surgery has acceptable outcomes; the presence of IE or concomitant procedures is a significant health detriment in these patients. Our study highlights the need for careful patient management and more in-depth research in this area to improve patient outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of infective endocarditis (IE) in patients undergoing redo mitral valve (MV) surgery was evaluated. The outcomes of all the patients and the patients' specific characteristics were recorded. The patients were analyzed to further the research of IE in this population.
METHOD
METHODS
This was a retrospective review of patients admitted for redo MV surgery with a prospective follow-up of electronic medical records at King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, from 2009 to 2019. Pre/intra/post-operative factors contributing to mortality, morbidity, and freedom of adverse events were analyzed.
RESULT
RESULTS
A total of 211 patients underwent redo MV surgery, and 41 patients (19.4%) had IE; and 51% of this subset of patients, 21 individuals, developed IE after the initial MV surgery. MV stenosis was moderate/severe in 50 patients. Furthermore, MV regurgitation was present in 89 patients. Multivariate analysis of the data revealed multiple factors influencing mortality: age, peripheral vascular disease, concomitant procedures, peripheral vascular disease, red blood cell transfusions, preoperative mechanical valves, and active IE. In-hospital Mortality was 10.9%. The one-, five-, and ten-year survival was 88%, 79%, and 69% across all patients.
CONCLUSION
CONCLUSIONS
Although redo MV surgery has acceptable outcomes; the presence of IE or concomitant procedures is a significant health detriment in these patients. Our study highlights the need for careful patient management and more in-depth research in this area to improve patient outcomes.
Identifiants
pubmed: 39354596
doi: 10.1186/s13019-024-03063-5
pii: 10.1186/s13019-024-03063-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
581Informations de copyright
© 2024. The Author(s).
Références
Zubarevich A, Szczechowicz M, Zhigalov K, Rad AA, Vardanyan R, Easo J, et al. Surgical redo mitral valve replacement in high-risk patients: the real-world experience. J Card Surg. 2021;36(9):3195–204.
doi: 10.1111/jocs.15787
pubmed: 34227147
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561–632.
doi: 10.1093/eurheartj/ehab395
pubmed: 34453165
Chairs ASTIECGWC, Pettersson GB, Coselli JS, Writing C, Pettersson GB, Coselli JS, et al. 2016 the American Association for thoracic surgery (AATS) consensus guidelines: Surgical treatment of infective endocarditis: executive summary. J Thorac Cardiovasc Surg. 2017;153(6):1241–58. e29.
doi: 10.1016/j.jtcvs.2016.09.093
Mehaffey HJ, Hawkins RB, Schubert S, Fonner C, Yarboro LT, Quader M, et al. Contemporary outcomes in reoperative mitral valve surgery. Heart. 2018;104(8):652–6.
doi: 10.1136/heartjnl-2017-312047
pubmed: 28982718
Fleissner F, Salman J, Naqizadah J, Avsar M, Meier J, Warnecke G, et al. Minimally invasive surgery in mitral valve endocarditis. Thorac Cardiovasc Surg. 2019;67(8):637–43.
doi: 10.1055/s-0038-1675342
pubmed: 30380574
Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC guidelines for the management of endocarditis: developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM). Eur Heart J. 2023;44(39):3948–4042.
doi: 10.1093/eurheartj/ehad193
pubmed: 37622656
Ahtela E, Oksi J, Porela P, Ekstrom T, Rautava P, Kyto V. Trends in occurrence and 30-day mortality of infective endocarditis in adults: population-based registry study in Finland. BMJ Open. 2019;9(4):e026811.
doi: 10.1136/bmjopen-2018-026811
pubmed: 31005935
pmcid: 6500343
Anttila V, Malmberg M, Gunn J, Rautava P, Kyto V. Infective endocarditis and outcomes of mitral valve replacement. Eur J Clin Invest. 2021;51(9):e13577.
doi: 10.1111/eci.13577
pubmed: 33931874
David TE, Gavra G, Feindel CM, Regesta T, Armstrong S, Maganti MD. Surgical treatment of active infective endocarditis: a continued challenge. J Thorac Cardiovasc Surg. 2007;133(1):144–9.
doi: 10.1016/j.jtcvs.2006.08.060
pubmed: 17198801
Ivanovic B, Trifunovic D, Matic S, Petrovic J, Sacic D, Tadic M. Prosthetic valve endocarditis - A trouble or a challenge? J Cardiol. 2019;73(2):126–33.
doi: 10.1016/j.jjcc.2018.08.007
pubmed: 30389305
Luciani N, Mossuto E, Ricci D, Luciani M, Russo M, Salsano A, et al. Prosthetic valve endocarditis: predictors of early outcome of surgical therapy. A multicentric study. Eur J Cardiothorac Surg. 2017;52(4):768–74.
doi: 10.1093/ejcts/ezx169
pubmed: 28575189
Vohra HA, Whistance RN, Roubelakis A, Burton A, Barlow CW, Tsang GM, et al. Outcome after redo-mitral valve replacement in adult patients: a 10-year single-centre experience. Interact Cardiovasc Thorac Surg. 2012;14(5):575–9.
doi: 10.1093/icvts/ivs005
pubmed: 22294560
pmcid: 3735849
Onorati F, Mariscalco G, Reichart D, Perrotti A, Gatti G, De Feo M, et al. Hospital Outcome and Risk indices of Mortality after redo-mitral valve surgery in potential candidates for transcatheter procedures: results from a European Registry. J Cardiothorac Vasc Anesth. 2018;32(2):646–53.
doi: 10.1053/j.jvca.2017.09.039
pubmed: 29325846
Zia Khan M, Zahid S, Khan MU, Kichloo A, Jamal S, Mannan Khan Minhas A, et al. Redo Surgical mitral valve replacement versus transcatheter mitral valve in Valve from the National Inpatient Sample. J Am Heart Assoc. 2021;10(17):e020948.
doi: 10.1161/JAHA.121.020948
pubmed: 34459226
pmcid: 8649266
Rutledge R, Kim BJ, Applebaum RE. Actuarial analysis of the risk of prosthetic valve endocarditis in 1,598 patients with mechanical and bioprosthetic valves. Arch Surg. 1985;120(4):469–72.
doi: 10.1001/archsurg.1985.01390280061013
pubmed: 3985792
Boeder NF, Dorr O, Rixe J, Weipert K, Bauer T, Bayer M, et al. Endocarditis after interventional repair of the mitral valve: review of a dilemma. Cardiovasc Revasc Med. 2017;18(2):141–4.
doi: 10.1016/j.carrev.2016.11.003
pubmed: 27890554
Keenan NM, Newland RF, Baker RA, Rice GD, Bennetts JS. Outcomes of redo valve surgery in indigenous australians. Heart Lung Circ. 2019;28(7):1102–11.
doi: 10.1016/j.hlc.2018.05.198
pubmed: 30139596